Kinaset Therapeutics
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Kinaset Therapeutics Closes $103M for Asthma Drug
Kinaset Therapeutics, developing an inhalable pan-JAK inhibitor for severe asthma, has raised $103 million in Series B funding.
The round was co-led by RA Capital Management and Forge Life Science Partners with participation from EQT Life Sciences, Vivo Capital, and Schroders Capital.
Key Highlights
- Inhalable pan-JAK inhibitor (frevecitinib)
- Targets severe asthma patients
- Minimal systemic side effects
Company Overview
Kinaset Therapeutics is developing frevecitinib, an inhalable pan-JAK inhibitor designed to target lung inflammation in severe asthma patients while minimizing systemic effects.
Company Info
Investors (4)
Share
Related Reports
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Ema Raises $77M Series B to Expand Its Enterprise AI Employee Platform
Ema raised a $77 million Series B led by Creaegis, bringing total funding to $140 million as it scales AI agents across enterprise workflows.
Chamelio Raises $26M Series A for AI-Native Legal Operations
Chamelio raised a $26 million Series A led by Entrée Capital to replace legacy contract-management systems with agentic legal operations.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free